| Product Name | Lapaquistat-d9 Acetate |
| Product Code | DA-L116-b |
| Chemical name | Lapaquistat-d9 Acetate |
| Synonyms | 1-[2-[(3R,5S)-1-[3-(Acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic Acid-d9; (3R-trans)-1-[[1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic Acid-d9; TAK 475-d9; |
| Impurity | NA |
| CAS Number | 1292841-28-1 |
| Alternate CAS # | NA |
| Molecular form | C33H32D9ClN2O9 |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 654.20 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | amines,chiral standards,heterocycles,enzyme inhibitors,stable isotopes,pharmaceutical standards,intermediates,fine chemicals |
| Boiling Point | NA |
| Applications | A novel labelled squalene synthase inhibitor. Lapaquistat acetate decreased plasma cholesterol and triglyceride levels, by lowering lipoproteins containing apoB100. Treatment with Lapaquistat acetate increased collagen concentration and transformed coronary plaques into fibromuscular plaques. Lapaquistat acetate also suppressed the expression of matrix metalloproteinase-1 and plasminogen activator inhibitor-1 in the plaque and increased peripheral coenzyme Q10 levels. Antiarteriosclerotics. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
